全年增速1.5%!医药流通存量博弈周期,头部阵营有何不败密码?

医药研究社
Feb 28

进入存量整合阶段。来源|医药研究社医药流通行业的分化早已不是新鲜事,但2025年财报数据仍让人惊叹于差距的悬殊。根据同花顺-问财数据,A股24家上市医药流通企业中,9家发布的业绩预告呈现“4盈5亏”格局:国药一致、建发致新、开开实业、药易购实现盈利,其中国药一致以11.35亿元预告净利润中值领跑;合富中国、塞力医疗、达嘉维康、润达医疗、海王生物均在亏损,其中润达医疗、海王生物的预告亏损额中值均超5...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10